![]() ![]() Additionally, the same Healthcare Common Procedure Coding System (“HCPCS”) “A Code” will be used on claims to private payers. In December 2016, the Centers for Medicare & Medicaid Services (CMS) granted NETSPOT Transitional Pass-Through status under an A-code (A9587) for drug reimbursement, effective Jan. HCPCS code A9587 for Gallium ga-68, dotatate, diagnostic, 0.1 millicurie as maintained by CMS falls under Diagnostic and Therapeutic Radiopharmaceuticals. The company is seeking to grow its network of radiopharmacy partners from 20 sites to more than 40 sites over the first half of 2017. are now delivering 400 doses of NETSPOT per month. AAA and its radiopharmacy partners around the U.S. Food and Drug Administration (FDA) on June 1, 2016, 23 months from the first pre-Investigational New Drug meeting with the agency. NETSPOT, a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor-positive NETs, was approved by the U.S. In June 2016, Netspot (kit for the preparation of gallium Ga-68 dotatate injection) was approved for medical use in the United States. The ability to image these patients with this compound is crucial to the success of any molecular imaging program. I believe this technology will lead to significant changes in patient management and will guide decisions for targeted therapies.” HCPCS Code A9587 for Gallium ga-68, dotatate, diagnostic. advises nursing mothers to pump and discard breastmilk for 12 hours after a dose, based on isotope's physical half-life alone. It can found in lactating breasts in higher than usual amounts. Food and Drug Administration approved Netspot, the first-ever kit for the preparation of. Gallium Ga 68 dotatate is used for localization of somatostatin receptor positive neuroendocrine tumors. was used for a decade in Europe (Graham, 2017), on June 1, 2016, the U.S. Lale Kostakoglu, M.D., MPH, chief, nuclear medicine and molecular imaging, at the Icahn School of Medicine at Mount Sinai, stated “We as molecular imagers are very pleased to see this valuable imaging modality be finally integrated into a national management algorithm for neuroendocrine tumors. Radioactive gallium (Ga) 68 dotatate is a positron emitting analogue of. Ultimately, I believe the use of NETSPOT will lead to improved outcomes for patients.” This advance in imaging capability provides treating physicians with enormous insights, enabling better directed surgeries and enhanced decision making regarding different therapeutic options. announced that its product NETSPOT (gallium Ga-68 dotatate) has been included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology version 1.2017 update for the evaluation of neuroendocrine tumors (NETs).Įric Liu, M.D., FACS, neuroendocrine tumor surgeon and co-director, The Neuroendocrine Institute at Rocky Mountain Cancer Center and HealthOne, stated, “As a physician that sees more than 400 patients with NETs per year, I am very grateful to have NETSPOT available and included in the NCCN Guidelines. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |